1. Home
  2. CION vs AVXL Comparison

CION vs AVXL Comparison

Compare CION & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CION

CION Investment Corporation

HOLD

Current Price

$9.47

Market Cap

496.0M

Sector

Finance

ML Signal

HOLD

Logo Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp.

HOLD

Current Price

$5.01

Market Cap

397.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CION
AVXL
Founded
2011
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
496.0M
397.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CION
AVXL
Price
$9.47
$5.01
Analyst Decision
Sell
Strong Buy
Analyst Count
1
3
Target Price
$8.50
$22.00
AVG Volume (30 Days)
442.0K
2.0M
Earning Date
11-06-2025
02-11-2026
Dividend Yield
12.70%
N/A
EPS Growth
N/A
N/A
EPS
0.49
N/A
Revenue
$244,923,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.51
$2.86
52 Week High
$12.71
$13.99

Technical Indicators

Market Signals
Indicator
CION
AVXL
Relative Strength Index (RSI) 43.80 67.85
Support Level $9.30 $4.67
Resistance Level $9.74 $4.44
Average True Range (ATR) 0.23 0.29
MACD -0.01 0.18
Stochastic Oscillator 26.90 89.40

Price Performance

Historical Comparison
CION
AVXL

About CION CION Investment Corporation

CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Company's portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Share on Social Networks: